Top
Topic: Immunotherapy Of Cancer: Future Possible Therapy For Metastatic Cancer

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 31 Aug 2019

Guest Editor(s)

  • Dr. Pravin D. Potdar
    Professor of Genetics and Stem cell Research, Dr. A.P.J Abdul Kalam Education & Research Centre, Mumbai, India.

    E-mail

Special Issue Introduction

Cancer is one of the most common leading cause of death in men and women worldwide. Most of the cancers are diagnosed at the last stage. Therefore, clinicians find difficulty in giving treatment to these patients which resulted in an overall high mortality rate in cancer patients. Radiation therapy or chemotherapy is the major treatment for most of the cancers. However, due to severe side effects, most of the cancer patients stumble to death. Immunotherapy is an alternative innovative therapy for cancer, which uses cancer patient’s own body cells to stimulate their own immune system to kill cancer cells. There are different types of immunotherapies such as treatment of cancer patients with monoclonal antibodies, cancer vaccine, immune-check points inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapies. CAR T-cell therapy is one of the promising therapies, where immune T cells are modified in the lab in such a way that they can destroy cancer cells alone leaving normal cells live. Few CAR T-cell therapies are approved for use in the treatment of advanced leukemia and lymphomas. CAR T-cell therapies are only being used in clinical trials for those patients who are not responding to conventional therapy. In 2018, Professor James Allison from M.D. Anderson Cancer Centre, Texas, USA, received the Noble prize for his outstanding contribution in the field of immunotherapy of cancer. Since then, there is great excitement in the field immunotherapy of cancer. Therefore, the Journal of Cancer Metastasis and Treatment (JCMT) has the great privilege to introduce this important hot topic for their readers through this special issue on “Immunotherapy of Cancer - Future Possible Therapy for Metastatic Cancer.” This issue will address important technical and theoretical aspects of the development of immunotherapy for various cancers. This special issue will also emphasize its early clinical drug development, clinical trials, translational research, therapeutic effectiveness and successful management for the treatment of cancer patients. This special issue will be a great asset and reference book for young cancer researchers, who are beginning their research on these novel therapies of cancer.

Keywords

Immunotherapy, Cancer, CAR-T cells, monoclonal antibody, Immune T cells, cancer metastasis

Submission Deadline

31 Aug 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/jcmt
Submission Deadline: 31 Aug 2019
Contacts: Lijun Jin, managing editor, editorialoffice@jcmtjournal.com

Planned Papers

Type: Review

Title: Multi-layered control of PD-L1 expression in EBV-associated gastric cancer

Authors: Christos Miliotis, Frank J Slack

Affiliations: Harvard Medical School/Beth Israel Deaconess Medical Center

Abstract: Gastric cancer (GC) is the fifth most common cancer worldwide and around 10% of the cases are characterized by ubiquitous EBV infection of the cancer cells. One of the main features of EBV-associated GC (EBVaGC) is high lymphocytic infiltration and high expression of immune checkpoint proteins, including programmed death-ligand 1 (PD-L1). This highlights EBVaGC as a strong candidate for immune checkpoint blockade therapy, which has been recently approved for advanced cases of GC. Understanding the underlying mechanisms that control PD-L1 expression in EBVaGC can also indicate new targets for combination therapy. This review provides the most recent updates on the multi-layered control of PD-L1 expression in EBVaGC.


Type: Review

Title: Novel Immunotherapeutic Approaches in Head and Neck Cancer

Authors: Heft Neal ME1, Brenner JC1, Spector ME1, Swiecicki PL2

Affiliations: 1. Department of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI.
2. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI

Abstract: Head and neck cancer is a clinically and molecularly heterogeneous disease which represents the sixth most common cancer worldwide. Despite advancements in surgical and radiation techniques, around 50% of patients with head and neck cancer will develop metastatic disease.  Treatment of metastatic head and neck cancer has been dependent on cytotoxic chemotherapy and forays into immunotherapy have been met with failure.  However, with the advent of PD-1 inhibitors, immunotherapy has finally found success. Nivolumab and pembrolizumab have been demonstrated to offer survival benefit and are approved treatments. Despite the promise of currently approved immunotherapies, there continues to be low response rates and additional strategies are needed. Head and neck tumors exhibit numerous derangements in the tumor microenvironment that aid in immune evasion and may serve as targets for future therapies. Here, alterations in the immune microenvironment and current therapeutic strategies are reviewed with a focus on novel immunologic approaches.


Published Articles

This special issue is now open for submission.